期刊
FUTURE MEDICINAL CHEMISTRY
卷 8, 期 12, 页码 1469-1484出版社
FUTURE SCI LTD
DOI: 10.4155/fmc-2016-0053
关键词
antifungals; drugs; fungi; glucosylceramide; sphingolipids; targets
资金
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao de Amparo a Pesquisa do estado do Rio de Janeiro (FAPERJ)
- NIH [AI56168, AI100631, AI116420]
- Veterans Affairs Program in Biomedical Laboratory Research and Development [I01BX002624]
Invasive fungal infections have significantly increased in the last few decades. Three classes of drugs are commonly used to treat these infections: polyenes, azoles and echinocandins. Unfortunately each of these drugs has drawbacks; polyenes are toxic, resistance against azoles is emerging and echinocandins have narrow spectrum of activity. Thus, the development of new antifungals is urgently needed. In this context, fungal sphingolipids have emerged as a potential target for new antifungals, because their biosynthesis in fungi is structurally different than in mammals. Besides, some fungal sphingolipids play an important role in the regulation of virulence in a variety of fungi. This review aims to highlight the diverse strategies that could be used to block the synthesis or/and function of fungal sphingolipids.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据